.png)
NextGen Biomed 2027
.svg)
18 - 19 March 2027
InterContinental London - The O2, UK
InterContinental London - The O2, UK
Alexia Hapeshi
Associate Research Director,
NanoSyrinx
Andrew Creese
Scientific Director, Analytical Development at Immunocore,
Immunocore
Aneesh Karatt Vellatt
Chief Scientific Officer,
Maxion Therapeutics
Annarita Di Tacchio
Research Scientist ,
AstraZeneca
Antti Vuolanto
CEO,
Herantis Pharma
Bryce Nelson
Head of Antibody Discovery,
Orion Pharma
Carolina Säll
Principal Scientist,
Novo Nordisk
Christian Graf
Fellow Scientific Office Biologics,
Novartis
Christian Rohlff
CEO,
Oxford Biotherapeutics
Christine Rothe
CDO,
iOmx Therapeutics
Colette Johnston
VP,
EnaraBio Limited
Ekaterina Grinko
Business Innovation & Partnerships Lead Obesity/GLP-1,
Novo Nordisk
Erik Anders Vernet
Sr Dir,
Novo Nordisk A/S
Giuliana Vozza
Senior Scientist,
AstraZeneca
Hanne Nielsen
Director, Center for Biopharmaceuticals and Biobarriers in Drug Delivery,
University of Copenhagen
Hans Melo
Chief Executive Officer,
Menten Biotechnology Labs
Héloïse Quillay
Principal Scientist, Lab Head,
Sanofi
Hilde Stals
Director CMC,
Argenx BVBA
Hilmar Warenius
CEO and Co-founder,
Syntherix Ltd
Jamie Baker
Professor of Chemistry,
University College London
Kai Hilpert
Associate Professor Infection and Immunity,
London City University
Knud Jørgen Jensen
Professor,
Copenhagen University
Krzysztof Brzózka
CSO,
Ryvu Therapeutics
Lorenzo Albertazzi
Associate Professor TU/e Department of Biomedical Engineering,
Eindhoven University of Technology
Maria Sörhede Winzell
Senior Director,
Camurus
Mariusz Olejniczak
CEO,
WPD Pharmaceuticals
Mark Frigerio
VP, Head of Platform Technology & Science,
Bicycle Therapeutics plc
Matthew Burrell
Associate Director,
AstraZeneca
Michael Davies
Chief Executive Officer,
Carocell Bio
Michael Wallington
Director, Oncology RWE & Epidemiology,
Pfizer
Olga Obrezanova
AI Principal Scientist,
AstraZeneca
Origène Nyanguile
Professor,
HES-SO Valais-Wallis
Paul Sauter
Senior Director Chemistry & Bioconjugation,
VERAXA Biotech GmbH
Philip Beer
CSO,
Step Pharma
Preeti Bakrania
Head of Partnerships, Platforms,
LifeArc
Rachel Evans
Director Translational Medicine,
AstraZeneca
Ruud Coumans
Director of Protein Chemistry and Project Leader Antibody-Drug Conjugates,
Byondis
Stefan Dübel
Director,
Technische Universitat Braunschweig
Steve Hood
Director, Oligonucleotide ADME Strategy, DMPK,,
GSK
Thomas Jostock
Associate Director,
Novartis Pharma
Thomas Powell
Senior Scientist,
Immunocore
Vaios Karanikas
Translational Biomarker Sciences Group Head,
Roche
Winston Haynes
Vice President, Computational Sciences and Engineering,
LabGenius
Our Esteemed Sponsors for NextGen Biomed 2027
Platinum Sponsors
Gold Sponsors
Silver Sponsors
NOF Europe GmbH
Silver Sponsor
NOF CORPORATION, the leading commercial supplier of drug delivery products through R&D to commercial scale, provides activated PEGs for protein modification, single molecular PEGs for ADCs, Polysorbate 80 for formulation of biological medicines, PEG lipids and ionizable lipids for lipid nanoparticle (LNP) formulations. NOF's LNP platform composed of COATSOME® SS Series, novel biodegradable ionizable lipid, demonstrates superior endosomal escape and provides high protein expression with extremely low systemic toxicity. The platform can be applied to gene delivery, gene editing, nucleic acid vaccine and in vitro transfection. It is capable of encapsulating pDNA, siRNA and mRNA, and delivering these to various organs and tissues. NOF’s LNP platform is becoming adopted in clinical planning by NOF collaborators.
.png?length=600&name=011642ee-be6f-428c-a980-112f96a780c1-2-5668375logo-MicrosoftTeams-image-(41).png)
Bronze Sponsors
-(1)-(1)-58ca14.png?length=600&name=81995b69-e5b1-45ad-a889-8693e6151276-2-5668375logo-Nuclera_Logo_Principal_Blue-(3)-(1)-(1)-58ca14.png){kind=logo}
Network & Programme Sponsors
Lonza AG
Network & Programme Sponsor
As a dedicated CDMO serving the healthcare industry, we bring life-enhancing and life-saving treatments to market for our customers and their patients. We are a pioneer and world leader in the CDMO industry, setting the pace with cutting-edge science, smart technology, and lean manufacturing. United by a common purpose, we turn our customers’ breakthrough innovations into viable therapies and manufacture the medicines of tomorrow.
Founded in Switzerland in 1897, our company is the first and original CDMO. Today, we bring together a team of 20,000 colleagues across five continents to deliver integrated offerings that meet the complex needs of our global customer community.
.jpeg?length=600&name=82caff72-ab1d-41bf-aa58-38a89a3b5d74-2-5668375logo-NOVILYTIC-Logo-FINISH-ValerieP23Jun2020v1_-For-Mira-Awards-(002).jpeg){kind=logo}
